FIRST‐LINE L‐ASPARAGINASE‐BASED CHEMOTHERAPY PLUS RADIOTHERAPY IS ACTIVE IN STAGE I/II EXTRANODAL NK/T‐CELL LYMPHOMA: RESULTS FROM PEKING UNIVERSITY CANCER HOSPITAL